Benzinga's Daily Brief On Trending Tickers For April 20, 2022: Procter & Gamble, Lululemon, Netflix, And More

Benzinga's "Daily Brief On Trending Tickers" features the top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.

The data on the trending tickers is compiled from a list of most-discussed tickers on the popular Reddit forum WallStreetBets.

Netflix Inc NASDAQ:NFLX shares slumped over 27% during Wednesday's pre-market session after announcing less-than-expected first-quarter revenue and a loss of net paid subscribers.

ASML Holding NV NASDAQ:ASML shares are trading 5.97% higher during Wednesday's pre-market session amid the company's better than expected first-quarter EPS and sales results.

Abbott Laboratories NYSE:ABT shares are trading 2.68% lower during Wednesday's pre-market session after reporting better than expected EPS and revenue results.

Procter & Gamble Co NYSE:PG shares are trading 1.31% higher during Wednesday's pre-market session after the company reported better than expected EPS and sales growth.

Sono Group NV NASDAQ:SEV shares are trading 5.92% lower during Wednesday's pre-market session due to profit-taking after the company reported its 2021 financial results on Tuesday. The stock jumped over 65% during Tuesday's trading session.

Also Read: No Parallels Between Netflix And Tesla, Says Ark Analyst

Anthem Inc NYSE:ANTM beat estimated earnings by 5.63%, reporting an EPS of $8.25. At the same time, revenue grew by $5.79 billion over the same period last year, causing shares to move 2.31% higher during Wednesday's pre-market session.

Lululemon Athletica Inc NASDAQ:LULU aims to double its revenue to $12.5 billion by 2026 through its Power of Three ×2 growth strategy, which includes a plan to fold men's and digital revenues and quadruple international revenues relative to 2021.

Windtree Therapeutics Inc NASDAQ:WINT shares are trading 40% higher during Wednesday's pre-market session as the company announced topline results from its phase 2 seismic study of istaroxime in early cardiogenic results.